Company Directory - Argenx
Company Details - Argenx

Argenx
WebsiteBelgium (Ghent), Belgium
ISIN: NL0011375019
Argenx is a biotechnology company focused on developing innovative therapies for patients with severe autoimmune diseases and cancer. The company employs a unique approach that harnesses the power of the immune system to discover and develop therapeutic antibodies.
CCI Score
CCI Score: Argenx
79.03
-0.04%
Latest Event
argenx 2023 Annual Report: Strong Commitment to Ethical and Social Responsibility
The 2023 Argenx Annual Report details comprehensive non-financial disclosures that highlight robust adherence to ethical practices, strong labor and human rights standards, anti-discrimination and anti-corruption measures, and firm environmental compliance. No material breaches were reported, demonstrating a progressive commitment to social responsibility and a resistance to authoritarian practices.
Take Action
So what can you do? Support Argenx by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
LEADER
Argenx is currently rated as a Leader.
Latest Events
- DEC312023
The 2023 Argenx Annual Report details comprehensive non-financial disclosures that highlight robust adherence to ethical practices, strong labor and human rights standards, anti-discrimination and anti-corruption measures, and firm environmental compliance. No material breaches were reported, demonstrating a progressive commitment to social responsibility and a resistance to authoritarian practices.
+90
Labor Relations and Human Rights Practices
October 10
argenx's report emphasizes a strong culture of compliance and ethical behavior. The detailed disclosure concerning labor rights, human rights, diversity, and anti-corruption measures—with no identified breaches—indicates a proactive stance against authoritarian and exploitative practices, aligning well with progressive, anti-fascist values.
Alternatives
Raleigh, USA
56.52

Cranbury, United States
-15.14

Basel, Switzerland
-19.75
Seattle, United States
-38.14

Menlo Park, United States
-49.80
Corporation
0.00

Corporation
0.00

Corporation
-52.53

Corporation
-26.78
New York, United States
30.41
Corporate Financials
- Revenue
- 2024
- $100.00M
- Total Assets
- 2024
- $800.00M
- Operating Income
- 2024
- -$50.00M
- Total Equity
- 2024
- $300.00M
Employees: 500
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 621511
- Medical Laboratories
- 541711
- Research and Development in Biotechnology